<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01827774</url>
  </required_header>
  <id_info>
    <org_study_id>12-015</org_study_id>
    <nct_id>NCT01827774</nct_id>
  </id_info>
  <brief_title>Soft Tissue Graft for Repair of Pelvic Organ Prolapse</brief_title>
  <acronym>POP</acronym>
  <official_title>A Post-Market Study of Surgisis® Soft Tissue Graft for Repair of Pelvic Organ Prolapse</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Cook Group Incorporated</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Cook Group Incorporated</source>
  <brief_summary>
    <textblock>
      The purpose of this Study is to collect information about the performance of the Surgisis®&#xD;
      Soft Tissue Graft (&quot;Study Product&quot;) for the repair of pelvic organ prolapse in women.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>March 2013</start_date>
  <completion_date type="Actual">April 17, 2017</completion_date>
  <primary_completion_date type="Actual">April 17, 2017</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Rate of recurrence of pelvic organ prolapse</measure>
    <time_frame>12 months</time_frame>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">31</enrollment>
  <condition>Pelvic Organ Prolapse</condition>
  <arm_group>
    <arm_group_label>Surgisis® Soft Tissue Graft</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Surgisis® Soft Tissue Graft</intervention_name>
    <description>Surgisis® Soft Tissue Graft for pelvic organ prolapse repair</description>
    <arm_group_label>Surgisis® Soft Tissue Graft</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Patients in need of transvaginal surgical repair of primary (i.e., de novo) pelvic&#xD;
             organ prolapse.&#xD;
&#xD;
          -  POPQ = stage 2 or 3 in the vaginal compartment with the leading edge of prolapse&#xD;
             (i.e., more severe prolapse)&#xD;
&#xD;
          -  At least one symptom associated with prolapse (e.g., any of the following including&#xD;
             but not limited to vaginal bulge, vaginal pain/discomfort, voiding dysfunction, manual&#xD;
             reduction (digitation) needed for defecation, fecal incontinence, dyspareunia)&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Age &lt; 18 years&#xD;
&#xD;
          -  BMI &gt; 40&#xD;
&#xD;
          -  Not medically fit for transvaginal surgery under general or spinal anesthesia&#xD;
&#xD;
          -  Active UTI at the time of the index procedure as determined by urine culture&#xD;
&#xD;
          -  Vaginal atrophy (Note: Patient may be included after vaginal atrophy has been&#xD;
             effectively treated.)&#xD;
&#xD;
          -  Prior placement of synthetic mesh or biologic graft for pelvic organ prolapse&#xD;
&#xD;
          -  A history of cervical, ovarian, uterine, endometrial, vaginal, vulval, colon, rectal&#xD;
             or bladder cancer&#xD;
&#xD;
          -  Currently planned obliterative surgical repair for pelvic organ prolapse&#xD;
&#xD;
          -  Systemic infection at the time of surgery&#xD;
&#xD;
          -  Requires chronic immunosuppressive therapy, including steroids or cytotoxic agents&#xD;
&#xD;
          -  Pregnant, breastfeeding or planning pregnancy during the study period&#xD;
&#xD;
          -  Previous diagnosis of collagen disorder (i.e., Marfan's, Ehlers-Danlos)&#xD;
&#xD;
          -  Physical allergies or cultural objections to the receipt of porcine products&#xD;
&#xD;
          -  Life expectancy of less than 12 months&#xD;
&#xD;
          -  Ongoing participation in an investigational device or drug trial&#xD;
&#xD;
          -  Currently undergoing evaluation or treatment for chronic pelvic pain (e.g., pain as a&#xD;
             result of interstitial cystitis, endometriosis, vulvodynia, pelvic congestion&#xD;
             syndrome)&#xD;
&#xD;
          -  Active vaginal infection at the time of the index procedure&#xD;
&#xD;
          -  History of pelvic inflammatory disease&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Peking University People's Hospital</name>
      <address>
        <city>Beijing</city>
        <zip>100044</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>February 2018</verification_date>
  <study_first_submitted>April 3, 2013</study_first_submitted>
  <study_first_submitted_qc>April 5, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 10, 2013</study_first_posted>
  <last_update_submitted>February 14, 2018</last_update_submitted>
  <last_update_submitted_qc>February 14, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">February 15, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Pelvic organ prolapse</keyword>
  <keyword>Graft repair</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Prolapse</mesh_term>
    <mesh_term>Pelvic Organ Prolapse</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

